These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 28370242)

  • 1. Thalassemia: Yesterday, Today, Tomorrow.
    Hadjidemetriou M
    Am J Hematol; 2017 Jun; 92(6):490-492. PubMed ID: 28370242
    [No Abstract]   [Full Text] [Related]  

  • 2. Thalassemia treatment and prevention in Uva Province, Sri Lanka: a public opinion survey.
    Mudiyanse RM
    Hemoglobin; 2006; 30(2):275-89. PubMed ID: 16798653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
    Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Iron-chelating treatment].
    Vullo C; Di Palma A; De Sanctis V; Borgatti L; Atti G
    Haematologica; 1989 Oct; 74(5 Suppl):241-51. PubMed ID: 2512211
    [No Abstract]   [Full Text] [Related]  

  • 5. Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications.
    Kolnagou A; Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):287-95. PubMed ID: 19814674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
    Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot study on parental stress and behavioral adjustment to the thalassemia major disease process in children undergoing iron-chelation in western Taiwan.
    Kuo HT; Peng CT; Tsai MY
    Hemoglobin; 2006; 30(2):301-9. PubMed ID: 16798655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients.
    Olivieri NF; Koren G; St Louis P; Freedman MH; McClelland RA; Templeton DM
    Semin Hematol; 1990 Apr; 27(2):101-4. PubMed ID: 2190316
    [No Abstract]   [Full Text] [Related]  

  • 9. Iron chelation.
    Chandy M
    J Assoc Physicians India; 1991 Sep; 39(9):665-6. PubMed ID: 1814896
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN; El Rassi F; Taher AT
    Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron-chelation therapy with oral chelators in patients with thalassemia major.
    Uygun V; Kurtoglu E
    Hematology; 2013 Jan; 18(1):50-5. PubMed ID: 23321010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot study on the "quality of life" as reflected by psychosocial adjustment of children with thalassemia major undergoing iron-chelating treatment in western Taiwan.
    Kuo HT; Tsai MY; Peng CT; Wu KH
    Hemoglobin; 2006; 30(2):291-9. PubMed ID: 16798654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
    Economou M; Printza N; Teli A; Tzimouli V; Tsatra I; Papachristou F; Athanassiou-Metaxa M
    Acta Haematol; 2010; 123(3):148-52. PubMed ID: 20185899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
    Borgna-Pignatti C; Rugolotto S; De Stefano P; Zhao H; Cappellini MD; Del Vecchio GC; Romeo MA; Forni GL; Gamberini MR; Ghilardi R; Piga A; Cnaan A
    Haematologica; 2004 Oct; 89(10):1187-93. PubMed ID: 15477202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron chelation therapy for patients with sickle cell disease and iron overload.
    Inati A; Khoriaty E; Musallam KM; Taher AT
    Am J Hematol; 2010 Oct; 85(10):782-6. PubMed ID: 20721892
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of iron chelation therapy with deferoxamine.
    Cohen A
    Semin Hematol; 1990 Apr; 27(2):86-90. PubMed ID: 2190321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
    Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):1-15. PubMed ID: 18274978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of long term iron chelation treatment with deferoxamine.
    Davis BA; Porter JB
    Adv Exp Med Biol; 2002; 509():91-125. PubMed ID: 12572991
    [No Abstract]   [Full Text] [Related]  

  • 20. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.